Download Cardiogenic shock management

Cardiogenic shock management
January 14th, 2016
10h30-12h
About the aetiologies of cardiogenic shock,
which proposition(s) is/are correct?
A) Myocardial infarction is responsible for ≈ 40%
B) Myocardial infarction is responsible for ≈ 75%
C) The 2nd leading cause is pulmonary embolism
D) The 2nd leading cause is acute myocarditis
E) The ischemic aetiology has decreased from 50% in 30 years
About the aetiologies of cardiogenic shock,
which proposition(s) is/are correct?
A) Myocardial infarction is responsible for ≈ 40%
B) Myocardial infarction is responsible for ≈ 75%
C) The 2nd leading cause is pulmonary embolism
D) The 2nd leading cause is acute myocarditis
E) The ischemic aetiology has decreased from 50% in 30 years
What is/are the predictive factor(s) of poor
prognosis in cardiogenic shock?
A) Diabetes
B) Renal insufficiency
C) Older age
D) Use of vasopressors and inotropes
E) Atrial fibrillation onset
What is/are the predictive factor(s) of poor
prognosis in cardiogenic shock?
A) Diabetes
B) Renal insufficiency
C) Older age
D) Use of vasopressors and inotropes
E) Atrial fibrillation onset
Mortality of cardiogenic shock:
A) Is ≈ 45%
B) Is ≈ 20%
C) Has decreased over the past 20 years
D) Is higher in case of non ischemic versus ischemic cause
E) Is mostly due to liver failure
Mortality of cardiogenic shock:
A) Is ≈ 45%
B) Is ≈ 20%
C) Has decreased over the past 20 years
D) Is higher in case of non ischemic versus ischemic cause
E) Is mostly due to liver failure
About Serelaxin, which of the following
proposition(s) is/are correct?
A) Is a recombinant form of the human Relaxin hormone
B) Serelaxin is produced during a normal pregnancy
C) Is a potent vasodilator
D) Has major diuretic effects
E) Has shown improved survival in acute heart failure with
reduced LVEF
About Serelaxin, which of the following
proposition(s) is/are correct?
A) Is a recombinant form of the human Relaxin hormone
B) Serelaxin is produced during a normal pregnancy
C) Is a potent vasodilator
D) Has major diuretic effects
E) Has shown improved survival in acute heart failure with
reduced LVEF
About Ularitide, which of the following
proposition(s) is/are correct?
A) Is a myosin activator
B) Is a synthetic analogous of the human natriuretic peptide
urodilatin
C) His main target is in the renal collecting tubules
D) Could decrease renin-angiotensinaldosterone system (RAAS)
activation
E) TRUE-AHF is a phase III multicentre randomised clinical trial
evaluating the efficacy and safety of Ularitide
About Ularitide, which of the following
proposition(s) is/are correct?
A) Is a myosin activator
B) Is a synthetic analogous of the human natriuretic peptide
urodilatin
C) His main target is in the renal collecting tubules
D) Could decrease renin-angiotensinaldosterone system (RAAS)
activation
E) TRUE-AHF is a phase III multicentre randomised clinical trial
evaluating the efficacy and safety of Ularitide
What is/are the ventricular assistance device(s)
that can be used in cardiogenic shock?
A) Intra-Aortic Balloon Pump (IABP)
B) The Impella
C) The TandemHeart system
D) veno-venous ECMO
E) Veno-arterial ECMO
What is/are the ventricular assistance device(s)
that can be used in cardiogenic shock?
A) Intra-Aortic Balloon Pump (IABP)
B) The Impella
C) The TandemHeart system
D) veno-venous ECMO
E) Veno-arterial ECMO
Which of the following proposition(s) is/are
contra-indication(s) to ECMO?
A) Severe Mitral regurgitation
B) Severe aortic regurgitation
C) Intracardiac thrombus
D) On going sepsis
E) Severe Right ventricular dysfunction
Which of the following proposition(s) is/are
contra-indication(s) to ECMO?
A) Severe Mitral regurgitation
B) Severe aortic regurgitation
C) Intracardiac thrombus
D) On going sepsis
E) Severe Right ventricular dysfunction